Aktuelles zu Inzidenz, Risikofaktoren und Behandlung von venösen Thrombosen an ungewöhnlichen Stellen

Der Begriff „venöse Thrombosen an ungewöhnlicher Stelle“ bezieht sich auf ungewöhnliche Erscheinungsformen von venösen Thromboembolien (VTE), die außerhalb der unteren Extremitäten und der Lungenarterien auftreten. Die Behandlung der VTE an ungewöhnlichen Stellen ist aufgrund der Heterogenität des klinischen Erscheinungsbildes und der prädisponierenden Faktoren sowie aufgrund des Mangels an qualitativ hochwertiger Evidenz zur Festlegung von Behandlungsstrategien eine Herausforderung. Ziel dieser Übersichtsarbeit ist es, die verfügbaren Erkenntnisse zusammenzufassen und praktische Hinweise für die Behandlung der VTE an ungewöhnlichen Stellen zu präsentieren.

Schlüsselwörter

venöse Thromboembolie - Splanchnikusvenenthrombose - Thrombose der Hirnvenen - Verschluss der Netzhautvenen - Blutung - Antikoagulationsbehandlung

Publication History

Article published online:
10 April 2024

• Literatur

• 1 Thatipelli MR, McBane RD, Hodge DO. et al. “Survival and recurrence in patients with splanchnic vein thromboses”. Clin Gastroenterol Hepatol 2010; 8 (02) 200-205 DOI: 10.1016/J.CGH.2009.09.019.
• 2 Riva N. et al. “Clinical history and antithrombotic treatment of incidentally detected splanchnic vein thrombosis: a multicentre, international prospective registry”. Lancet Haematol 2016; 3 (06) e267-e275 DOI: 10.1016/S2352-3026(16)30020-5.
• 3 Bach AM. et al. “Portal vein evaluation with US: comparison to angiography combined with CT arterial portography”. Radiology 1996; 201 (01) 149-154 DOI: 10.1148/RADIOLOGY.201.1.8816536.
• 4 Rajesh S, Mukund A, Arora A. “Imaging Diagnosis of Splanchnic Venous Thrombosis”. Gastroenterol Res Pract 2015; 2015 DOI: 10.1155/2015/101029.
• 5 de Stefano V, Martinelli I. “Splanchnic vein thrombosis: clinical presentation, risk factors and treatment”. Intern Emerg Med 2010; 5 (06) 487-494 DOI: 10.1007/S11739-010-0413-6.
• 6 Ageno W. et al. “Long-term Clinical Outcomes of Splanchnic Vein Thrombosis: Results of an International Registry”. JAMA Intern Med 2015; 175 (09) 1474-1480 DOI: 10.1001/JAMAINTERNMED.2015.3184.
• 7 Condat B. et al. “Current outcome of portal vein thrombosis in adults: Risk and benefit of anticoagulant therapy”. Gastroenterology 2001; 120 (02) 490-497 DOI: 10.1053/gast.2001.21209.
• 8 Spaander MCW, Hoekstra J, Hansen BE. et al. “Anticoagulant therapy in patients with non-cirrhotic portal vein thrombosis: effect on new thrombotic events and gastrointestinal bleeding”. J Thromb Haemost 2013; 11 (03) 452-459 DOI: 10.1111/JTH.12121.
• 9 Candeloro M. et al. “Anticoagulant therapy for splanchnic vein thrombosis: an individual patient data meta-analysis”. Blood Adv 2022; 6 (15) 4516-4523 DOI: 10.1182/BLOODADVANCES.2022007961.
• 10 Ageno W, Beyer-Westendorf J, Garcia DA. et al. “Guidance for the management of venous thrombosis in unusual sites”. J Thromb Thrombolysis 2016; 41 (01) 129-143 DOI: 10.1007/S11239-015-1308-1.
• 11 Ageno W. “Treatment of Atypical Clots”. Hamostaseologie 2022; 42 (01) 10-18 DOI: 10.1055/A-1669-3336.
• 12 Di Nisio M, Valeriani E, Riva N. et al. “Anticoagulant therapy for splanchnic vein thrombosis: ISTH SSC Subcommittee Control of Anticoagulation”. J Thromb Haemost 2020; 18 (07) 1562-1568 DOI: 10.1111/JTH.14836.
• 13 “S2k-Leitlinie Federführende Fachgesellschaft: Deutsche Gesellschaft für Angiologie-Gesellschaft für Gefäßmedizin”. 2023
• 14 Naymagon L. et al. “The efficacy and safety of direct oral anticoagulants in noncirrhotic portal vein thrombosis”. Blood Adv 2020; 4 (04) 655-666 DOI: 10.1182/BLOODADVANCES.2019001310.
• 15 Ageno W. et al. “Rivaroxaban for the treatment of noncirrhotic splanchnic vein thrombosis: an interventional prospective cohort study”. Blood Adv 2022; 6 (12) 3569-3578 DOI: 10.1182/BLOODADVANCES.2022007397.
• 16 Elie Plessier A. et al. “Rivaroxaban Prophylaxis in Noncirrhotic Portal Vein Thrombosis”. NEJM Evidence 2022; 1 (12) DOI: 10.1056/EVIDOA2200104.
• 17 Mohan BP, Aravamudan VM, Khan SR. et al. “Treatment response and bleeding events associated with anticoagulant therapy of portal vein thrombosis in cirrhotic patients: Systematic review and meta-analysis”. Ann Gastroenterol 2020; 33 (05) 521-527 DOI: 10.20524/AOG.2020.0503.
• 18 Smalberg JH. et al. “Risks and benefits of transcatheter thrombolytic therapy in patients with splanchnic venous thrombosis”. Thromb Haemost 2008; 100 (06) 1084-1088 DOI: 10.1160/TH08-01-0015.
• 19 Riva N, Ageno W. “Approach to thrombosis at unusual sites: Splanchnic and cerebral vein thrombosis”. Vasc Med 2017; 22 (06) 529-540 DOI: 10.1177/1358863X17734057.
• 20 Ropper AH, Klein JP. “Cerebral Venous Thrombosis”. N Engl J Med 2021; 385 (01) 59-64 DOI: 10.1056/NEJMRA2106545.
• 21 Dentali F. et al. “Long-term outcomes of patients with cerebral vein thrombosis: a multicenter study”. J Thromb Haemost 2012; 10 (07) 1297-1302 DOI: 10.1111/J.1538-7836.2012.04774.X.
• 22 Ferro JM, Canhão P, Stam J. et al. “Prognosis of Cerebral Vein and Dural Sinus Thrombosis: Results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT)”. Stroke 2004; 35 (03) 664-670 DOI: 10.1161/01.STR.0000117571.76197.26.
• 23 Dentali F. et al. “Long-term outcomes of patients with cerebral vein thrombosis: A multicenter study”. Journal of Thrombosis and Haemostasis 2012; 10 (07) 1297-1302 DOI: 10.1111/j.1538-7836.2012.04774.x.
• 24 Dentali F, Crowther M, Ageno W. “Thrombophilic abnormalities, oral contraceptives, and risk of cerebral vein thrombosis: a meta-analysis”. Blood 2006; 107 (07) 2766-2773 DOI: 10.1182/blood-2005-09-3578.
• 25 Martinelli I. “Cerebral vein thrombosis”. Thromb Res 2013; 131 (Suppl. 01) DOI: 10.1016/S0049-3848(13)70022-7.
• 26 Leal Rato M, Bandeira M, Romão VC. et al “Neurologic Manifestations of the Antiphospholipid Syndrome – an Update”. Current Neurology and Neuroscience Reports 2021; Springer 21 (08) DOI: 10.1007/s11910-021-01124-z.
• 27 Ferro JM. et al. “European Stroke Organization guideline for the diagnosis and treatment of cerebral venous thrombosis – endorsed by the European Academy of Neurology”. Eur J Neurol 2017; 24 (10) 1203-1213 DOI: 10.1111/ene.13381.
• 28 Gangat N. et al. “Cerebral venous thrombosis and myeloproliferative neoplasms: A three-center study of 74 consecutive cases”. Am J Hematol 2021; 96 (12) 1580-1586 DOI: 10.1002/AJH.26336.
• 29 Ferro JM. et al. “European Stroke Organization guideline for the diagnosis and treatment of cerebral venous thrombosis – endorsed by the European Academy of Neurology”. Eur J Neurol 2017; 24 (10) 1203-1213 DOI: 10.1111/ENE.13381.
• 30 Ferro JM. et al. “Safety and Efficacy of Dabigatran Etexilate vs Dose-Adjusted Warfarin in Patients With Cerebral Venous Thrombosis: A Randomized Clinical Trial”. JAMA Neurol 2019; 76 (12) 1457-1465 DOI: 10.1001/JAMANEUROL.2019.2764.
• 31 Connor P. et al. “Safety and efficacy of rivaroxaban in pediatric cerebral venous thrombosis (EINSTEIN-Jr CVT)”. Blood Adv 2020; 4 (24) 6250-6258 DOI: 10.1182/BLOODADVANCES.2020003244.
• 32 Yaghi S. et al. “Direct Oral Anticoagulants Versus Warfarin in the Treatment of Cerebral Venous Thrombosis (ACTION-CVT): A Multicenter International Study”. Stroke 2022; 53 (03) 728-738 DOI: 10.1161/STROKEAHA.121.037541.
• 33 Field TS. et al. “Study of Rivaroxaban for Cerebral Venous Thrombosis: A Randomized Controlled Feasibility Trial Comparing Anticoagulation With Rivaroxaban to Standard-of-Care in Symptomatic Cerebral Venous Thrombosis”. Stroke 2023; 54 (11) DOI: 10.1161/STROKEAHA.123.044113.
• 34 Nepal G. et al “Safety and efficacy of Direct Oral Anticoagulants in cerebral venous thrombosis: A meta-analysis”. Acta Neurologica Scandinavica 2022; John Wiley and Sons Inc 145 (01) 10-23 DOI: 10.1111/ane.13506.
• 35 Riat R, Gomez K. “Addendum to guidelines on the investigation and management of venous thrombosis at unusual sites (Br. J. Haematol. 2012;159:28-38): Use of Direct Oral Anticoagulants”. Br J Haematol 2022; 198 (01) 46-49 DOI: 10.1111/BJH.18189.
• 36 Song P, Xu Y, Zha M. et al. “Global epidemiology of retinal vein occlusion: a systematic review and meta-analysis of prevalence, incidence, and risk factors”. J Glob Health 2019; 9 (01) DOI: 10.7189/JOGH.09.010427.
• 37 Paciullo F, Giannandrea D, Virgili G. et al. “Role of Increased Lipoprotein (a) in Retinal Vein Occlusion: A Systematic Review and Meta-analysis”. TH Open 2021; 5 (03) e295-e302 DOI: 10.1055/S-0041-1732803.
• 38 Russell MW. et al. “Lack of association between Lp(a) and retinal vein occlusion in a single institution and US national database”. Can J Ophthalmol 2023; DOI: 10.1016/J.JCJO.2023.10.007.
• 39 Hernández JL. et al. “Antiphospholipid syndrome and antiphospholipid antibody profile in patients with retinal vein occlusion”. Thromb Res 2020; 190: 63-68 DOI: 10.1016/J.THROMRES.2020.04.005.
• 40 Romiti GF. et al. “Inherited and acquired thrombophilia in adults with retinal vascular occlusion: A systematic review and meta-analysis”. J Thromb Haemost 2020; 18 (12) 3249-3266 DOI: 10.1111/JTH.15068.
• 41 Paciullo F. et al. “Antithrombotic treatment of retinal vein occlusion: a position statement from the Italian Society on Thrombosis and Haemostasis (SISET)”. Blood Transfus 2022; 20 (04) 341-347 DOI: 10.2450/2022.0276-21.
• 42 Lazo-Langner A, Hawel J, Ageno W. et al. “Low molecular weight heparin for the treatment of retinal vein occlusion: a systematic review and meta-analysis of randomized trials”. Haematologica 2010; 95 (09) 1587-1593 DOI: 10.3324/HAEMATOL.2010.023614.
• 43 Valeriani E. et al. “Antithrombotic treatment for retinal vein occlusion: a systematic review and meta-analysis”. J Thromb Haemost 2023; 21 (02) 284-293 DOI: 10.1016/J.JTHA.2022.10.003.
• 44 Cugati S. et al. “Retinal vein occlusion and vascular mortality: pooled data analysis of 2 population-based cohorts”. Ophthalmology 2007; 114 (03) 520-524 DOI: 10.1016/J.OPHTHA.2006.06.061.
• 45 Khan Z, Almeida DRP, Rahim K. et al. “10-Year Framingham risk in patients with retinal vein occlusion: a systematic review and meta-analysis”. Can J Ophthalmol 2013; 48 (01) DOI: 10.1016/J.JCJO.2012.08.017.